Connect your AI

PTHS PTHS Accrued Progress Collections and Price Adjustments

Accrued Progress Collections and Price Adjustments at other companies

Ocular TherapeutixOCUL

——

ExelixisEXEL

——

TTR

Turn Therapeutics Inc. Common StockTTRX

——

Other financials

Income statement

Revenue$10.9M—

Gross profit$9.2M—

Operating income-$13.1M-614%

Net income-$10.2M-420%

EPS (diluted)-$3.09+3.7%

Balance sheet

Cash & equivalents$32.0M+24,250%

Total debt$29.6M—

Total equity$35.1M+937%

Total assets$145.4M+15,855%

Cash flow

Operating cash flow-$13.1M-1,977%

CapEx$194.0K—

Free cash flow-$13.3M-2,008%

Valuation

Market cap$98.22M+75.4%

Enterprise value$95.89M—

P/S3.6×—

Profitability

Gross margin79.6%—

Operating margin-157.7%—

Net margin-186.2%—

FCF margin-60.8%—

Returns & leverage

Return on equity-333.8%—

Debt / equity0.8×—

Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's accrued progress collections and price adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is PTHS's accrued progress collections and price adjustments?: PTHS (PTHS) reported accrued progress collections and price adjustments of $1.03M in Q1 2026.